Priority setting at the clinical level: the case of nusinersen and the Norwegian national expert group
Abstract Background Nusinersen is one of an increasing number of new, expensive orphan drugs to receive authorization. These drugs strain public healthcare budgets and challenge principles for resource allocation. Nusinersen was introduced in the Norwegian public healthcare system in 2018. A nationa...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | BMC Medical Ethics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12910-021-00623-5 |